Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy.

Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy.

OBJECTIVE:To evaluate the survival outcomes and prognostic factors of patients with advanced hepatocellular carcinoma (HCC) who underwent stereotactic ablative radiotherapy (SABR). METHODS:This retrospective study evaluated patients with advanced HCC who underwent SABR between December 2007 and July...

Full description

Bibliographic Details
Main Authors:	Cheng-Hsiang Lo, Jen-Fu Yang, Ming-Yueh Liu, Yee-Min Jen, Chun-Shu Lin, Hsing-Lung Chao, Wen-Yen Huang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5435316?pdf=render

Similar Items

Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma
by: Jen-Fu Yang, et al.
Published: (2022-11-01)

Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis
by: Po-Lung Cheng, et al.
Published: (2023-04-01)

The prognostic utility of IGF-1 in hepatocellular carcinoma treated with stereotactic body radiotherapy
by: Ahmed Allam Mohamed, et al.
Published: (2025-01-01)

Stereotactic ablative radiotherapy for primary renal cell carcinoma
by: Daniel X. Yang, et al.
Published: (2024-01-01)

The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences
by: Yulin Hu, et al.
Published: (2022-09-01)

Radiofrequency ablation versus stereotactic body radiotherapy for recurrent hepatocellular carcinoma: a multicenter, propensity score matching analysis
by: Zi-Hui Ma, et al.
Published: (2025-03-01)

Vertebral compression fracture after stereotactic ablative radiotherapy in patients with oligometastatic bone lesions from hepatocellular carcinoma
by: Tae Hyung Kim, et al.
Published: (2023-07-01)

Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis
by: Young‐Seok Seo, et al.
Published: (2016-11-01)

Advances in Radiobiology of Stereotactic Ablative Radiotherapy
by: Bin Qiu, et al.
Published: (2020-08-01)

Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
by: Yukinori Matsuo
Published: (2023-02-01)

Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma
by: Jongmoo Park, et al.
Published: (2019-09-01)

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma
by: Rohit K. Raj, et al.
Published: (2023-12-01)

The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology
by: Steven Eric Finkelstein, et al.
Published: (2011-01-01)

Adrenal oligometastasis cured with stereotactic ablative radiotherapy
by: Julia Malone, BSC, et al.
Published: (2020-11-01)

Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment
by: Rachel Gravell, et al.
Published: (2024-10-01)

A framework for exactrac dynamic commissioning for stereotactic radiosurgery and stereotactic ablative radiotherapy
by: Ben Perrett, et al.
Published: (2022-01-01)

Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early‐stage non‐small‐cell lung cancer: a population‐based study
by: Hung‐Jen Chen, et al.
Published: (2024-08-01)

Stereotactic radiofrequency ablation of subcardiac hepatocellular carcinoma: a case-control study
by: Peter Schullian, et al.
Published: (2019-01-01)

Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity.
by: Jean-Emmanuel Bibault, et al.
Published: (2013-01-01)

Treatment Outcomes of Hepatocellular Carcinoma Patients who underwent Stereotactic Body Radiotherapy
by: Paytai Rordlamool, et al.
Published: (2022-07-01)

Stereotactic Microwave Ablation of Hepatocellular Carcinoma: The Impact of Tumor Size and Minimal Ablative Margin on Therapeutic Success
by: Antonia-Maria Pausch, et al.
Published: (2022-12-01)

Utility of Radiomics for Predicting Patient Survival in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With Stereotactic Body Radiotherapy
by: Kui Wu, et al.
Published: (2020-10-01)

Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
by: Tse, R, et al.
Published: (2008)

Stereotactic ablative radiotherapy for primary kidney cancer – An international patterns of practice survey
by: Katherine Taplin, et al.
Published: (2025-01-01)

Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma
by: Daniel Huang, et al.
Published: (2024-11-01)

Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial
by: Liang-Cheng Chen, et al.
Published: (2019-03-01)

Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-alone in Unresectable Hepatocellular Carcinoma (HCC)
by: Chi Leung Chiang, et al.
Published: (2023-10-01)

Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease
by: Nidal Salim, et al.
Published: (2024-06-01)

Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy
by: Younghee Park, et al.
Published: (2022-06-01)

Radiomics-Based Predictive Model of Radiation-Induced Liver Disease in Hepatocellular Carcinoma Patients Receiving Stereo-Tactic Body Radiotherapy
by: Po-Chien Shen, et al.
Published: (2022-03-01)

The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)
by: Moreno-Olmedo, E, et al.
Published: (2024)

The potential of integrating stereotactic ablative radiotherapy techniques with hyperfractionation for lung cancer
by: Chi‐Chuan Chiou, et al.
Published: (2024-08-01)

Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
by: Sundus Yahya, et al.
Published: (2018-07-01)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression
by: Chin-Beng Ho, et al.
Published: (2023-04-01)

Hypofractionated Stereotactic Radiotherapy after Transarterial Chemoembolisation Failure in an Unresectable Hepatocellular Carcinoma: A Case Presentation
by: Francesco Fiorica, et al.
Published: (2013-01-01)

Establishing the Role of Stereotactic Ablative Body Radiotherapy in Early-Stage Breast Cancer
by: Aisling Barry, et al.
Published: (2018-01-01)

Stereotactic ablative body radiotherapy for ventricular tachycardia: An alternative therapy for refractory patients
by: Carolina De La Pinta, et al.
Published: (2021-12-01)

Precision of image-guided spinal stereotactic ablative radiotherapy and impact of positioning variables
by: Charlotte Billiet, et al.
Published: (2022-04-01)

Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer
by: Kevin T. Tran, et al.
Published: (2023-03-01)

Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study
by: Xiaoquan Ji, et al.
Published: (2023-06-01)